Quantitative Benefit–Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial

Quantitative Benefit–Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial

Background The VOYAGER PAD (Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities) trial compared rivaroxaban (2.5 mg twice a day)...

Full description

Bibliographic Details
Main Authors: Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M. Bauersachs, Scott D. Berkowitz, Lloyd Haskell, Elliot S. Barnathan, Marc P. Bonaca
Format: Article
Language:English
Published: Wiley 2024-04-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
health state utilities
modeling
multi‐criteria decision analysis
peripheral artery disease
rivaroxaban
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.123.032782

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.123.032782

Similar Items